Print Share Email Send Email Your Name (required) Example: John Doe This field is required. Email Address (required) Error: Please enter a valid sender email address. Example: email@example.com CC Me This field is required. Please enter a valid email address. Recipient Email Address(es) (required - use a semicolon to separate multiple addresses) Separate multiple email address with semi-colons (up to 5). This field is required. Please enter a valid email address. One or more of your email addresses are invalid. Please review before submitting. Subject Subject for your email. Message (Maximum characters: 1,000) Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Alexander SA, Lala A. Alexander S.A., & Lala A Alexander, Steven A., and Anuradha Lala. Galactic-HF: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. Hurst's the Heart Updates, 11 December 2020. McGraw Hill, 2020. AccessCardiology. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=555013§ionid=252838824APA Citation Alexander SA, Lala A. Alexander S.A., & Lala A Alexander, Steven A., and Anuradha Lala. (2020). Galactic-hf: omecamtiv mecarbil in chronic heart failure with reduced ejection fraction. Fuster V. Fuster V Fuster, Valentin. Hurst's the heart updates. McGraw Hill. https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=555013§ionid=252838824.MLA Citation Alexander SA, Lala A. Alexander S.A., & Lala A Alexander, Steven A., and Anuradha Lala. "Galactic-HF: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction." Hurst's the Heart Updates Fuster V. Fuster V Fuster, Valentin. McGraw Hill, 2020, https://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=555013§ionid=252838824. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Galactic-HF: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction by Steven A. Alexander, Anuradha Lala Listen + +Update to Chapter 70: The Diagnosis and Management of Chronic Heart Failure Study Summary + +Omecamtiv mecarbil is a selective cardiac myosin activator that augments sarcomere function and force of contraction without increased energy consumption. The GALACTIC-HF trial investigators randomly assigned 8,256 patients with chronic heart failure and reduced ejection fraction (≤35%) to receive omecamtiv mecarbil (25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart failure therapy. Over a median of 21.8 months, a primary-outcome event — a first heart failure event or cardiovascular-related death —occurred in 37.0% of the omecamtiv mecarbil group compared with 39.1% of the placebo group (HR 0.92; 95% CI 0.86-0.99; P = 0.03; see accompanying Hurst’s Central Illustration). Deaths from cardiovascular-related causes were noted for 19.6% of the omecamtiv mecarbil group and 19.4% of the placebo group (P = NS). No significant differences in secondary outcomes were found between the two groups, including change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptoms score or frequency of cardiac ischemic and ventricular arrhythmia events. Graphic Jump LocationView Full Size||Download Slide (.ppt) Commentary + +Study Strengths: This was a large, international, multicenter, placebo-controlled trial with few exclusion criteria, which enhances the external validity of the study. The trial excluded patients with systolic blood pressure <85 mmHg or an estimated glomerular filtration rate <20 ml/min/1.73 m2, which allowed the inclusion of sicker patients with hypotension or chronic kidney disease when compared to previous heart failure trials. +Study Limitations: The trial excluded patients over the age of 85 years and those with a clinically unstable condition. Only 7% of the patients self-reported as black, though this is higher than in many previous heart failure trials. Only 21% of the patients were women. Although the background therapy was generally excellent, only 19% of patients were receiving sacubitril–valsartan at baseline and only 2.6% were receiving a sodium–glucose cotransporter 2 inhibitor. Whether omecamtiv mecarbil would add incremental value in addition to these medications is unclear. +Next Steps/Clinical Perspective: This trial supports the hypothesis that selectively targeting the cardiac sarcomere with omecamtiv mecarbil to improve cardiac function can improve clinical outcomes. However, given the modest effect size on the primary outcome (absolute difference, 2.1 percentage points) and the low use of contemporary effective heart failure medications in the trial, omecamtiv mecarbil is unlikely to become a first-line treatment for heart failure. A heterogeneity of treatment effect was suggested by a potentially greater effect in patients with an ejection fraction ≤28%, compared with an ejection fraction >28%. Additional subgroup analyses may provide further insights into groups who may benefit more from omecamtiv mecarbil, such as patients who are sicker, with lower blood pressure or chronic kidney disease, for whom heart failure treatment options are lacking. Trial Reference + + + +Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N. Engl. J. Med. doi:10.1056/NEJMoa2025797.